Summary of Toxoplasma Surveillance Testing at Hospital A and B for Transplants Performed During the Post-surveillance Period
| . | Total . | Recipient Negative /Donor Positive . | Recipient Positive . | ||||
|---|---|---|---|---|---|---|---|
| D+/R− . | D+ or D−/R+ . | ||||||
| Hospital A | |||||||
| Transplant type | Number of patients | Number of patients | Number of tests | Parasitemia detected | Number of patients | Number of tests | Parasitemia detected (%) |
| Conventional | 96 | 12 | 121 | 0/12 | 20 | 208 | 0/20 |
| CD34+ selected PB | 140 | 11 | 148 | 0/11 | 19 | 277 | 0/19 |
| Cord blood +/−CD34+ selected PB | 38 | 0 | 0 | N/A | 7 | 132 | 1/7 (14%) |
| Total | 274 | 23 (8%) | 269 | 0/23 | 46 (17%) | 617 | 1/46 (2.2%) |
| Total | Recipient negative a | Recipient positive | |||||
| R− | R+ | ||||||
| Hospital B | |||||||
| Transplant type | Number of patients | Number of patients | Number of tests | Parasitemia detected | Number of patients tested | Number of tests | Parasitemia detected (%) |
| Cord±Haplo- identical CD34 + | 47 | 35 | 778 | 0/35 | 12 | 313 | 2/12 (16.7%)* |
| Alemtuzumab- TCD PB | 73 | 60 | 1259 | 0/60 | 13 | 278 | 2/13 (15.4%)** |
| Total | 120 | 95 (79%) | 2037 | 0/95 | 25 (21%) | 591 | 4/25 (16%) |
| . | Total . | Recipient Negative /Donor Positive . | Recipient Positive . | ||||
|---|---|---|---|---|---|---|---|
| D+/R− . | D+ or D−/R+ . | ||||||
| Hospital A | |||||||
| Transplant type | Number of patients | Number of patients | Number of tests | Parasitemia detected | Number of patients | Number of tests | Parasitemia detected (%) |
| Conventional | 96 | 12 | 121 | 0/12 | 20 | 208 | 0/20 |
| CD34+ selected PB | 140 | 11 | 148 | 0/11 | 19 | 277 | 0/19 |
| Cord blood +/−CD34+ selected PB | 38 | 0 | 0 | N/A | 7 | 132 | 1/7 (14%) |
| Total | 274 | 23 (8%) | 269 | 0/23 | 46 (17%) | 617 | 1/46 (2.2%) |
| Total | Recipient negative a | Recipient positive | |||||
| R− | R+ | ||||||
| Hospital B | |||||||
| Transplant type | Number of patients | Number of patients | Number of tests | Parasitemia detected | Number of patients tested | Number of tests | Parasitemia detected (%) |
| Cord±Haplo- identical CD34 + | 47 | 35 | 778 | 0/35 | 12 | 313 | 2/12 (16.7%)* |
| Alemtuzumab- TCD PB | 73 | 60 | 1259 | 0/60 | 13 | 278 | 2/13 (15.4%)** |
| Total | 120 | 95 (79%) | 2037 | 0/95 | 25 (21%) | 591 | 4/25 (16%) |
Abbreviations: N/A, not applicable; PB, peripheral blood; TCD, T-cell depleted.
a Includes patients with equivocal titres.
For hospital A routine surveillance was recommended for Toxoplasma seropositive recipients (R+) who underwent TCD PB and cord. Other groups were tested at clinician discretion. For hospital B, all transplants were included in surveillance testing.
* P value =.06, ** P value =.02.
Summary of Toxoplasma Surveillance Testing at Hospital A and B for Transplants Performed During the Post-surveillance Period
| . | Total . | Recipient Negative /Donor Positive . | Recipient Positive . | ||||
|---|---|---|---|---|---|---|---|
| D+/R− . | D+ or D−/R+ . | ||||||
| Hospital A | |||||||
| Transplant type | Number of patients | Number of patients | Number of tests | Parasitemia detected | Number of patients | Number of tests | Parasitemia detected (%) |
| Conventional | 96 | 12 | 121 | 0/12 | 20 | 208 | 0/20 |
| CD34+ selected PB | 140 | 11 | 148 | 0/11 | 19 | 277 | 0/19 |
| Cord blood +/−CD34+ selected PB | 38 | 0 | 0 | N/A | 7 | 132 | 1/7 (14%) |
| Total | 274 | 23 (8%) | 269 | 0/23 | 46 (17%) | 617 | 1/46 (2.2%) |
| Total | Recipient negative a | Recipient positive | |||||
| R− | R+ | ||||||
| Hospital B | |||||||
| Transplant type | Number of patients | Number of patients | Number of tests | Parasitemia detected | Number of patients tested | Number of tests | Parasitemia detected (%) |
| Cord±Haplo- identical CD34 + | 47 | 35 | 778 | 0/35 | 12 | 313 | 2/12 (16.7%)* |
| Alemtuzumab- TCD PB | 73 | 60 | 1259 | 0/60 | 13 | 278 | 2/13 (15.4%)** |
| Total | 120 | 95 (79%) | 2037 | 0/95 | 25 (21%) | 591 | 4/25 (16%) |
| . | Total . | Recipient Negative /Donor Positive . | Recipient Positive . | ||||
|---|---|---|---|---|---|---|---|
| D+/R− . | D+ or D−/R+ . | ||||||
| Hospital A | |||||||
| Transplant type | Number of patients | Number of patients | Number of tests | Parasitemia detected | Number of patients | Number of tests | Parasitemia detected (%) |
| Conventional | 96 | 12 | 121 | 0/12 | 20 | 208 | 0/20 |
| CD34+ selected PB | 140 | 11 | 148 | 0/11 | 19 | 277 | 0/19 |
| Cord blood +/−CD34+ selected PB | 38 | 0 | 0 | N/A | 7 | 132 | 1/7 (14%) |
| Total | 274 | 23 (8%) | 269 | 0/23 | 46 (17%) | 617 | 1/46 (2.2%) |
| Total | Recipient negative a | Recipient positive | |||||
| R− | R+ | ||||||
| Hospital B | |||||||
| Transplant type | Number of patients | Number of patients | Number of tests | Parasitemia detected | Number of patients tested | Number of tests | Parasitemia detected (%) |
| Cord±Haplo- identical CD34 + | 47 | 35 | 778 | 0/35 | 12 | 313 | 2/12 (16.7%)* |
| Alemtuzumab- TCD PB | 73 | 60 | 1259 | 0/60 | 13 | 278 | 2/13 (15.4%)** |
| Total | 120 | 95 (79%) | 2037 | 0/95 | 25 (21%) | 591 | 4/25 (16%) |
Abbreviations: N/A, not applicable; PB, peripheral blood; TCD, T-cell depleted.
a Includes patients with equivocal titres.
For hospital A routine surveillance was recommended for Toxoplasma seropositive recipients (R+) who underwent TCD PB and cord. Other groups were tested at clinician discretion. For hospital B, all transplants were included in surveillance testing.
* P value =.06, ** P value =.02.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
